Let's not forget about Abbott Laboratories' impressive streak of 52 consecutive annual dividend increases, which also makes ...

Abbott's strong innovation pipeline, including advancements in CGM systems, supports its market share gains and growth ...

Piper Sandler initiates coverage on Abbott with an Overweight rating, citing its diversified business model, strong medtech ...

This was the stock's third consecutive day of losses.

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report), ...

Adam Maeder, an analyst from Piper Sandler, has initiated a new Buy rating on Abbott Laboratories (ABT). Adam Maeder has given his Buy rating ...

Abbott (ABT) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Abbott Laboratories (ABT) stock saw a decline, ending the day at $114.88 which represents a decrease of $-3.25 or -2.75% from the prior close of $118.13. The stock opened at $117.5 and touched a low ...

Fintel reports that on September 19, 2024, Piper Sandler initiated coverage of Abbott Laboratories ( LSE:0Q15) with a Overweight recommendation. What is the Fund Sentiment?

Dividend stocks are all-weather investments for buy-and-hold investing because they can help reduce portfolio volatility ...

Let's consider two stocks trading well below $200 that have what it takes to do that: Novo Nordisk (NYSE: NVO) and DexCom ...

Then, in 2022, Abbott co-founded Lelapa AI with data scientist Pelonomi Moiloa. Their goal was to develop localized language ...